Waters completes combination with BD Biosciences to form high-throughput diagnostics platform
- Waters completed its combination with BD's biosciences division, forming a diagnostics-focused life sciences company for high-volume regulated testing.
- Organized into four divisions to scale high‑throughput testing, expand markets, and speed customer adoption via shared R&D.
- Appointed genome scientist Claire M. Fraser to the board, strengthening genomics leadership to guide regulated‑market product roadmaps.
Waters completes combination with BD biosciences to form diagnostics platform
Waters Corporation completes its previously announced combination with Becton, Dickinson and Company’s Biosciences & Diagnostic Solutions business on Feb. 9, 2026, creating a broad life sciences and diagnostics company focused on high-volume testing in regulated applications. The deal brings together complementary technologies across chemistry, physics and biology and expands Waters’ addressable market in clinical testing, biopharma development and materials science. Management frames the combination as a pivotal step to accelerate commercial execution and scale laboratory and diagnostic workflows worldwide.
Four-division structure to scale high-throughput testing
The combined company immediately organizes into four operating divisions — Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences — to support development and manufacturing of large and small molecules and to pursue high-growth adjacent markets. Waters emphasizes that the new structure is designed to leverage category-defining products and shared R&D to speed customer adoption of high-throughput and regulated testing solutions. Leadership says the integration aims to drive operational efficiencies, expand manufacturing and distribution capacity, and better serve regulated clinical, diagnostics laboratories and biopharma customers.
Governance boost with genomics expertise as strategic asset
Waters appoints genome scientist Claire M. Fraser, Ph.D., to its board effective on closing, increasing the board to 11 members and adding deep genomics and molecular diagnostics experience. Chairman Flemming Ørnskov and CEO Udit Batra stress that scientific leadership and governance are central to overseeing the enlarged company’s next growth phase and to aligning product road maps with regulated-market requirements. Management highlights the ability to combine scientific expertise across disciplines to address unmet customer needs and advance global health.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

